2020-08-25 kl. 08:30 (Regulatoriskt)

Interim Report Q2, 2020

2020-06-01 kl. 14:12 (Regulatoriskt)

Patent application submitted to protect new technology

2020-02-24 kl. 11:30 (Regulatoriskt)

Reinforcements in SpectraCure's organization

2019-10-16 kl. 11:02 (Regulatoriskt)

SpectraCure at Stora Aktiedagen in Gothenburg

2019-08-14 kl. 11:10 (Regulatoriskt)

SpectraCures new generation P18

2019-07-08 kl. 09:45 (Regulatoriskt)

Great attention for SpectraCure in Boston

2019-06-10 kl. 13:55 (Regulatoriskt)

SpectraCure presents results from Phase 1 study

2019-04-10 kl. 10:46 (Regulatoriskt)

New patient treatment, phase 2 initiated

2019-04-05 kl. 13:53 (Regulatoriskt)

SpectraCure files for a new patent

2019-03-29 kl. 15:49 (Regulatoriskt)

Status report for phase 2 study

2019-02-15 kl. 09:22 (Regulatoriskt)

More results from Phase 1 study

2019-01-28 kl. 14:02 (Regulatoriskt)

Results from clinical study for patient 9 and 10

2017-10-18 kl. 09:54 (Regulatoriskt)

Imaging material from clinical Phase 1 study

2017-10-03 kl. 14:07 (Regulatoriskt)

Concept study for next generation product completed

2017-08-25 kl. 08:46 (Regulatoriskt)

Full drug dose achieved in prostate trial

2017-07-05 kl. 08:45 (Regulatoriskt)

EU Grant awarded through Vinnova

2017-06-01 kl. 10:36 (Regulatoriskt)

Patent for dose control approved in Canada

2017-05-23 kl. 15:15 (Regulatoriskt)

Communiqué from the Annual General Meeting 2017

2017-04-24 kl. 09:58 (Regulatoriskt)

Patient treatments started in clinical Phase 1 study

2017-01-18 kl. 17:03 (Regulatoriskt)

SpectraCure decides on Set-off Issue